Meeting
2014 ASCO Annual Meeting
Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
Authors
Howard Safran
Brown University Oncology Research Group, Providence, RI
Howard Safran , Kimberly Perez , Kevin Charpentier , Trevor Clark Austin , Kalyan C. Mantripragada , Kenneth D. Bishop , Alise Lombardo , Lindsay Houlihan , Kristen Mitchell , Kayla Rosati , Diane Martel , Lynn Shaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT01744353
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4123)
DOI
10.1200/jco.2014.32.15_suppl.4123
Abstract #
4123
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2019 Gastrointestinal Cancers Symposium
Toxicity of FOLFOX-abraxane (FOLFOX-A) on phase II Brown University Oncology Group (BrUOG) trials.
First Author: Howard Safran
Poster
2024 ASCO Annual Meeting
Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial.
First Author: Choong-kun Lee
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez